2023-05-05-Capgemini-未来的制药厂是人体（英）_11页_2mb

Summary of Pharmaceutical Green Transformation Report

Overview

The report outlines a strategy for transforming the pharmaceutical sector to reduce environmental impacts through a "Green Horizon" vision. This approach emphasizes sustainability, using lifecycle analysis and innovative technologies to minimize emissions, waste, and resource use in medication development, distribution, and consumption.

Key Findings

• Medication production and use contribute significantly to environmental impacts, with data showing:
  • In France, 33% of healthcare GHG emissions come from medication purchase, totaling approximately 15.6 megatons of CO2e annually.
  • Globally, healthcare emissions equate to the output of about 514 coal-fired power plants, with pharmaceuticals being a major contributor in sectors like the UK's NHS.
• Lifecycle analysis reveals hotspot areas such as extraction, clinical trials, distribution, and patient use, where pollution, energy consumption, and waste are prevalent.
• The Green Horizon concept emerges from a prospective mental excursion, redefining medication as a "connected product and service" that integrates with the human body for sustainability gains.

Proposed Solutions and Opportunities

The report highlights several pathways for green transformation, supported by biopharma examples and tech trends:

• Lifecycle Optimization: Utilize virtual drug tests (e.g., simulation software) and AI-driven clinical trials to reduce resource-intensive processes.
• Sustainable Raw Materials: Shift to bio-based manufacturing using methods inspired by natural chemistry, such as fermentation-based processes.
• Efficient Distribution: Employ greener fuels, optimize packaging, and reduce transport emissions with direct-to-consumer distribution models.
• Personalized and Circular Design: Develop adaptable doses, companions apps, and eco-friendly packaging to enhance adherence and reduce waste.
• Innovative Delivery Systems: Envision connected devices like mRNA patches that deliver customized medication with full adherence, minimizing environmental footprints.
• Feasibility: Tech innovations, such as quantum computing for molecular design and synthetic biology, can make these changes viable for incremental improvements.

Transformation Levels and Roadmap

A phased roadmap balances environmental goals with practical constraints:

• Level 1 (6-12 months): Focus on digital and operational optimizations, like renewing energy sources and developing companion apps.
• Level 2 (12-24 months): Incorporate AI for personalized molecule design and regulated medical devices for better adherence.
• Level 3 (>36 months): Aim for advanced technologies like embedded electronic patches that recover and reuse components, symbolizing the Green Horizon ideal.

Challenges and Conclusion

• Sustainable transformation faces barriers, including regulatory constraints and patient resistance to changes in medication delivery.
• Industries must collaborate on both social awareness and technical innovations to drive progress.
• The Green Horizon serves as an aspirational target to foster creativity and incremental steps toward greener practices, applicable across sectors.
• The conclusion underscores that while not all changes may be feasible immediately, this forward-thinking approach can spur innovation and mitigate environmental impacts on a global scale.

Contact information is provided for further inquiries, and the report highlights Capgemini's role in driving such transformations through its expertise.